We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Cryopreserved Erythrocytes Processed for Blood Transfusion

By LabMedica International staff writers
Posted on 10 Apr 2012
Cryostorage of red blood cells (RBCs) represents a valid alternative to liquid storage, since units can be preserved safely for at least a decade while conserving cell viability.

Preservation of blood for transfusion purposes has represented a lifesaving advance in clinical practice over many years, but although cryostorage has attracted a great deal of attention clinically, little is known about the biochemistry and physiology of cryostored erythrocyte concentrates. More...


Specialists at the University of Tuscia (Viterbo, Italy) investigated cryostorage of RBCs through monitoring of cell processing steps, from fresh blood, to glycerolization, thawing, and deglycerolization, followed by washing. Whole blood was collected from 10 healthy donor volunteers into 63 mL of citrate phosphate dextrose (CPD) anticoagulant, and leukodepleted. All glycerolized RBC units were frozen and stored at −80 ± 10 °C in a mechanical freezer for at least 12 months.

The erythrocytes were monitored through repeated assays of standard parameters of mean cell volume (MCV), red cell distribution width-standard deviation (RDW-SD), the mean cell hemoglobin concentration (MCHC), and the hematocrit (Hct). These were determined with a CA 530-Oden hematology analyzer. Scanning electron microscopy was also performed. Other standard biological indicators, such as hemoglobin content, pH values both internal and in the supernatant, lactate levels, osmotic fragility and hemolysis, were also calculated.

Cell processing for cryostorage resulted in increased RBC volumes. Mean cell volume (MCV) increased significantly upon glycerolization, from 89.4 ± 4.5 fL of fresh RBCs to 126.04 ± 2.3 fL of glycerolized RBCs, while it remained constant at 129.6 ± 3.3 fL upon cryostorage even after thawing. Deglycerolization and washing restored lower MCV values 93.7 ± 5.9 fL, though they were still higher than controls. Shape alterations caused an increase in osmotic fragility and permeability to ions. A significant pH drop was observed which could not to be attributed to a higher metabolic rate, since the levels of lactate did not show substantial fluctuation during the cell processing steps tested in this study. The membrane anomalies reported are likely related to the hemolysis observed which preferentially affected the densest and oldest cell sub-populations, as confirmed by means of discontinuous density gradients. The CA 530-Oden hematology analyzer used in the study is manufactured by Medonic (Stockholm, Sweden).

The authors concluded that their results indicate that cryostorage itself in presence of glycerol does not significantly affect RBCs. Most of the alterations observed were related to cell processing and, in particular, to the increase of cytosolic glycerol as a consequence of the glycerolization step. Further studies might profitably investigate replacing glycerol with nonpenetrating cryoprotectants such as polyvinylpyrrolidone or polyethylene glycol, or the less toxic sucrose and trehalose.The study was published online on March 14, 2012, in the journal Blood Cells, Molecules, and Diseases.

Related Links:

University of Tuscia
Medonic



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.